loanDepot, Inc. filed a Form 8-K with the SEC on August 21, 2026, disclosing that it received a written notice from the New York Stock Exchange indicating its Class A Common Stock fell below the exchange's $1.00 minimum average closing price requirement over a consecutive 30 trading-day period.

Key Highlights

  • NYSE Notice received: loanDepot received written notice from the NYSE on August 21, 2026, citing non-compliance with Section 802.01C of the NYSE Listed Company Manual.
  • Price deficiency: The average closing price of the Company's Class A Common Stock was less than $1.00 per share over a consecutive 30 trading-day period.
  • Six-month cure period: The Company has six months from receipt of the Notice to regain compliance with the minimum share price requirement.
  • Compliance path: Compliance can be regained if, on the last trading day of any calendar month during the cure period, the stock has a closing price of at least $1.00 and a 30 trading-day average closing price of at least $1.00.
  • No immediate listing impact: According to the filing, the Notice has no immediate impact on the listing of the Common Stock on the NYSE, subject to compliance with other continued listing requirements.
  • Intent to notify: The Company stated it intends to notify the NYSE of its intent to regain compliance within 10 business days of receipt of the Notice, as required by Section 802.01C.

loanDepot Discloses NYSE Listing Deficiency and Six-Month Cure Window

According to the filing, loanDepot, Inc. (NYSE:LDI) received a written notice from the NYSE on August 21, 2026, stating the company was not in compliance with Section 802.01C of the NYSE Listed Company Manual. The deficiency arose because the average closing price of the Company's Class A Common Stock, $0.001 par value, fell below $1.00 per share over a consecutive 30 trading-day period. The filing states that the Notice does not affect the Company's business operations or its reporting obligations with the SEC.

The filing explains that under Section 802.01C, the Company has a six-month cure period following receipt of the Notice. During this period, compliance can be restored if, on the last trading day of any calendar month within the cure window, the Common Stock closes at or above $1.00 and maintains a 30 trading-day average closing price of at least $1.00. If the Company is unable to regain compliance within that period, the filing states that "the NYSE will initiate procedures to suspend and delist the Common Stock."

The filing also discloses an alternative path: if the Company determines it will cure the price condition through an action requiring shareholder approval, it must inform the NYSE, obtain shareholder approval no later than its next annual meeting of stockholders, and implement the action promptly thereafter. The filing was signed by David Hayes, Chief Financial Officer, and a press release related to the matter was attached as Exhibit 99.1. The filing notes that statements regarding the Company's ability to regain compliance are forward-looking and subject to risks and uncertainties described in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

What Was Disclosed

loanDepot disclosed receipt of an NYSE listing deficiency notice on August 21, 2026, related to its Class A Common Stock falling below the $1.00 minimum average closing price threshold, and outlined the six-month cure period available under NYSE rules.